2152 citations
,
November 2013 in “Urologia Internationalis” This study reviews the significant prevalence of organic etiologies, especially vascular causes, in erectile dysfunction among men under 40 and emphasizes thorough evaluation and consideration of treatment options like exercise and PDE-5 inhibitors.
140 citations
,
October 2008 in “Nature Genetics” 
111 citations
,
October 2008 in “Nature Genetics” In their study, Tim Spector and colleagues identified a new genetic association at chromosome 20p11.22 with male-pattern baldness, confirmed by the increased risk when combined with a known androgen receptor gene variant.
18 citations
,
March 2008 in “British Journal of Dermatology” This study found that finasteride 1 mg daily decreased 5alpha-dihydrotestosterone levels and improved hair growth in younger men with androgenetic alopecia, with higher initial hormone levels predicting better response.
57 citations
,
November 2006 in “International Journal of Cancer” This study found that the SRD5A2 A49T A variant is associated with an increased risk of prostate cancer, lower circulating 3α‐diolG levels, and a decreased risk of baldness.
25 citations
,
January 2006 in “British Journal of Dermatology” This study found that finasteride decreases DHT/T levels more significantly in the vertex scalp hair than in the occipital hair of patients with male pattern baldness.
76 citations
,
April 2005 in “Cancer Epidemiology, Biomarkers & Prevention” This study found that the AR-E211 A allele is associated with a lower risk of both metastatic prostate cancer and androgenetic alopecia in an Australian population.
32 citations
,
December 2004 in “BMC Public Health” This study found that trained observers using the Hamilton-Norwood classification were very reliable in assessing balding patterns, while men's self-assessments were moderately accurate compared to observers.
33 citations
,
October 2004 in “Archives of Dermatological Research” This study suggests that a larger prostate is associated with a higher prevalence of androgenetic alopecia, although the prostate size did not correlate with alopecia severity.
191 citations
,
December 2003 in “Journal of Investigative Dermatology” Male pattern baldness is largely genetic, linked to the androgen receptor gene, and may relate to certain health issues.
174 citations
,
November 2002 in “Expert Reviews in Molecular Medicine” This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.
21 citations
,
June 2002 in “PubMed” This study found an association between vertex baldness and prostate cancer, especially for high-grade tumors in men aged 60-69, suggesting a possible shared androgen pathway.
299 citations
,
March 2001 in “Journal of Investigative Dermatology” This study found that specific genetic markers near the androgen receptor gene are significantly more common in men with male pattern baldness, suggesting a genetic component in its development.
47 citations
,
January 2001 in “Journal of Investigative Dermatology” High testosterone to epitestosterone ratio in hair could predict male-pattern baldness.
581 citations
,
October 1998 in “Journal of The American Academy of Dermatology” In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.
54 citations
,
May 1998 in “Urology” This study demonstrates that patients with benign prostatic hyperplasia have a higher severity and frequency of male pattern baldness compared to a control group.
416 citations
,
September 1997 in “Journal of Investigative Dermatology” People with hair loss have more androgen receptors and enzymes in certain follicles, with men and women showing different patterns.
1040 citations
,
October 1992 in “The New England Journal of Medicine” In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.
